Agilus Diagnostics, a leading Indian diagnostic service provider and subsidiary of Fortis Healthcare, has unveiled its comprehensive obesity & metabolic health test suite designed for smarter weight management, early detection of insulin resistance, and long-term metabolic health monitoring.

The launch comes at a time of growing global attention on GLP-1–based therapies for obesity.

Obesity in India continues to surge, with nearly one in four women and two in five men now overweight or obese. In urban areas, prevalence has climbed to 30–40%, fueled by lifestyle and dietary changes. Experts say this trend highlights the urgent need for diagnostic tools that can aid prevention, guide clinical decisions, and monitor metabolic risks over time.

The Vital Shape panels provide tiered assessments to detect obesity-related risks early: Vital Shape Lite (72 parameters): It offers a strong baseline metabolic evaluation, including BMI, comprehensive metabolic profile (CMP), eGFR, CBC, lipid and thyroid profiles, HbA1c, fasting insulin, HOMA-IR, FIB-4, iron studies, and vitamin D & B12 status.

Vital Shape Core (80 parameters) includes all Lite tests plus hsCRP for cardiac inflammation and additional nutritional and metabolic markers. Vital Shape Ultra (86 parameters) is one of India’s most comprehensive obesity-focused suites, adding leptin and adiponectin, amylase and lipase, and PTH with calcium to assess fatty liver, chronic inflammation, and hormonal drivers of metabolic dysfunction.

Dr Anand K, Managing Director & CEO, Agilus Diagnostics, said: “We are witnessing a global shift in obesity care, especially with the increasing use of GLP-1–based therapies. As clinical practices evolve, diagnostics must evolve with them. Complete Care Vital Shape empowers clinicians with comprehensive insights into insulin resistance, fatty liver, metabolic syndrome and cardiometabolic disorders.

"These conditions that lead to obesity often remain silent for years, and early detection is crucial for preventive and personalised care. This suite reinforces our commitment to supporting evidence-based decision-making at a time when patient expectations and scientific guidance are rapidly changing.”

Dr Ajay Phadke, Director – Strategic Business Development, Agilus Diagnostics, added: “Over the last quarter, we have seen a sharp rise in enquiries for structured assessments around obesity management, high-insulin states and metabolic dysfunction.

"Complete Care Vital Shape positions Agilus among the select few offering such detailed, clinically oriented panels in this space. As the use of GLP-1 agonists increases, clinicians need deeper baseline evaluations and continuous monitoring to track metabolic risks — from fatty liver to cardiometabolic disorders.

This suite is built precisely for those needs, and we will continue expanding the portfolio based on real-world evidence and clinical utility.”

With GLP-1 medications gaining mainstream adoption for obesity management, clinicians emphasize the importance of baseline metabolic evaluation, ongoing monitoring, and early risk detection before, during, and after therapy.

The Complete Care Vital Shape suite aims to set the baseline for GLP-1 therapy and enable periodic monitoring to optimize treatment outcomes, according to Agilus Diagnostics.